Linagliptin Inpatient Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.

Also called NCT02004366

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 295 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02004366
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02004366. Randomized; no masking; primary purpose treatment. Start 2014-01 (actual); primary completion 2017-02 (actual). Results posted on 2018-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin Inpatient Trial
Intervention (Drug)
Linagliptin
Intervention (Drug)
Basal Bolus
Intervention (Drug)
Linagliptin
Intervention (Drug)
Linagliptin + 50% Glargine dose on discharge
Intervention (Drug)
Linagliptin + 80% Glargine
Lead sponsor
Emory University (class: other)
Collaborator
Boston Medical Center (class: other)
Collaborator
Rush University (class: other)
Collaborator
University of Denver (class: other)

Record details

Record id
cardio:ct-nct02004366
Content hash
7901df4e47b6e2e490e9f7358a5175f7ff3c82ee664c129a561d387aa64a2c4a